Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRYOBI: Obinutuzumab in Refractory Cryoglobulinemic Vasculitis
NCT07268521Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2026
- Primary completion
- May 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in cryoglobulinemic vasculitis, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Complete Clinical Response at 6 months. Started Jan 2026; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
cryoglobulinemic vasculitis
Beyond the preview
Go deeper on NCT07268521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268521.